Immunic (IMUX) Non Operating Income (2013 - 2026)
Immunic (IMUX) posted Non Operating Income of $647000.0 for Q1 2026, down 83.93% sequentially from $4.0 million in Q4 2025, and down 52.14% YoY from $1.4 million in Q1 2025.
Powered by 
Analysis
Immunic (IMUX) Non Operating Income (2013 - 2026) Analysis & Trends
Immunic has reported Non Operating Income for 14 years, with the latest figure at $647000.0 in Q1 2026.
- Quarterly Non Operating Income fell 52.14% year-over-year to $647000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 16.33% YoY) and the FY2025 annual result came in at $6.1 million, up 346.68% from the prior year.
- Non Operating Income fell to $647000.0 in Q1 2026 per IMUX's latest filing, from $4.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $4.0 million in Q4 2025 and troughed at -$5.7 million in Q1 2024.
- A 5-year average of $525882.4 and a median of $801000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income plunged 388.18% in 2024, then soared 783.11% in 2025.
- Over 5 years, Non Operating Income stood at $853000.0 in 2022, then surged by 112.08% to $1.8 million in 2023, then slumped by 74.79% to $456000.0 in 2024, then soared by 783.11% to $4.0 million in 2025, then tumbled by 83.93% to $647000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $647000.0, $4.0 million, and $414000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Immunic | 543.54 Mn | 543.54 Mn | - | 1.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Mn |
| Mar 31, 2026 | 647,000.00 |
| Dec 31, 2025 | 4.03 Mn |
| Sep 30, 2025 | 414,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | -5.70 Mn |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 801,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 853,000.00 |
| Sep 30, 2022 | -1.11 Mn |
| Jun 30, 2022 | -1.29 Mn |
| Mar 31, 2022 | 627,000.00 |
| Dec 31, 2021 | 536,000.00 |
| Sep 30, 2021 | -905,000.00 |